NAD+ precursor decreases atrial fibrillation susceptibility and duration in mice
Scientists treated old mice with the molecules SS-31 and NMN (nicotinamide mononucleotide) separately to improve different heart functions and when delivered together these molecules acted synergistically to recapitulate the function and metabolism of young hearts.
Researchers from the University of Maryland and the Veterans Affairs Maryland Health Center recently found that NMN improves mitochondrial NAD+ metabolism and mitochondrial health via SIRT3 in ischemic mice.
A study from Duke University indicated that NMN supplementation improves function in mice with heart disease via boosting NAD+ levels and SIRT3 activity.
Scientists found NMN administration preserved mitochondrial health and prevented heart failure in mice deficient in a molecule that makes them susceptible to heart disease.
Supplementing mice with nicotinamide mononucleotide (NMN) reverses age-related artery dysfunction, a key contributor to cardiovascular disease.
Ischemia, the inadequate blood supply to body parts, can lead to life-threatening conditions. Scientists found that NMN may be a new intervention for it.